Skip to main content
. 2023 Aug 31;6(8):e2331249. doi: 10.1001/jamanetworkopen.2023.31249

Figure 1. Study Flowchart.

Figure 1.

US Department of Veterans Affairs (VA) enrollees with a first positive SARS-CoV-2 test from January 1, 2022, to January 31, 2023, included in the study are presented.

aA total of 5683 veterans who received remdesivir, bamlanivimab-etesevimab, and casirivimab-imdevimab were excluded from the treatment and no treatment groups.